Effects of carboxypeptidase B treatment and elevated temperature on recombinant monoclonal antibody charge variants in cation-exchange chromatography analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Do Gyun | - |
dc.contributor.author | Kim, Hyoung Jin | - |
dc.contributor.author | Kim, Hong-Jin | - |
dc.date.available | 2019-01-22T14:23:33Z | - |
dc.date.issued | 2016-10 | - |
dc.identifier.issn | 0253-6269 | - |
dc.identifier.issn | 1976-3786 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/1747 | - |
dc.description.abstract | Charge variants (acidic and basic) of recombinant monoclonal antibodies (Mabs) have received much attention due to their potential biological effects. C-terminal lysine variants are common in Mabs and their proportion is affected by the manufacturing process. In the present study, changes of trastuzumab charge variants brought about by carboxypeptidase B treatment and subsequent storage at 8 or 37 A degrees C for up to 24 h were monitored by cation-exchange chromatography analysis to investigate the effects of C-terminal lysine cleavage and its subsequent reaction at 8 or 37 A degrees C. C-terminal lysine cleavage at 8 A degrees C reduced the fraction of basic species and had little effect on the fraction of acidic species. Analysis of individual peaks demonstrated that C-terminal lysine cleavage induced both increases and decreases in individual acidic variants, with the result that there was little overall change in the overall proportion of acidic species. It appeared that most of the basic variant Mab molecules but only a fraction of the acidic variant molecules had C-terminal lysines. Increasing the temperature to 37 A degrees C appeared to increase the fraction of acidic species and decrease main species significantly, without a similar change in basic species. These results indicate that length of exposure to elevated temperature is a critical consideration in charge variant analysis. | - |
dc.format.extent | 10 | - |
dc.publisher | PHARMACEUTICAL SOC KOREA | - |
dc.title | Effects of carboxypeptidase B treatment and elevated temperature on recombinant monoclonal antibody charge variants in cation-exchange chromatography analysis | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s12272-016-0818-5 | - |
dc.identifier.bibliographicCitation | ARCHIVES OF PHARMACAL RESEARCH, v.39, no.10, pp 1472 - 1481 | - |
dc.identifier.kciid | ART002155972 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000386351000014 | - |
dc.identifier.scopusid | 2-s2.0-84982141356 | - |
dc.citation.endPage | 1481 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1472 | - |
dc.citation.title | ARCHIVES OF PHARMACAL RESEARCH | - |
dc.citation.volume | 39 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Monoclonal antibody | - |
dc.subject.keywordAuthor | Charge variant | - |
dc.subject.keywordAuthor | Cation-exchange chromatography | - |
dc.subject.keywordAuthor | Carboxypeptidase | - |
dc.subject.keywordAuthor | C-terminal lysine | - |
dc.subject.keywordPlus | CELL-CULTURE | - |
dc.subject.keywordPlus | HETEROGENEITY | - |
dc.subject.keywordPlus | DEAMIDATION | - |
dc.subject.keywordPlus | TRASTUZUMAB | - |
dc.subject.keywordPlus | PROTEINS | - |
dc.subject.keywordPlus | CANCER | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.